EU Fines Google, Sprint Eyes Wireless Partners, and Alder Gaps Lower

Reports of a new wireless partnership are propelling Sprint stock higher

Managing Editor
Jun 27, 2017 at 10:31 AM
facebook twitter linkedin


U.S. stocks are slightly higher this morning, as Wall Street preps for a busy day. Among specific names on the move today are Google parent Alphabet Inc (NASDAQ:GOOGL), telecommunications specialist Sprint Corp (NYSE:S), and drugmaker Alder Biopharmaceuticals Inc (NASDAQ:ALDR). Here's a quick look at what's moving shares of GOOGL, S, and ALDR.

EU Fine Cuts Into Google

Google stock is down 1% to trade at $961.62, as it deals with the fallout from a record EU fine of $2.7 billion for favoring its own shopping results in search. Alphabet says it's considering an appeal of the ruling.

This is a bump in the road for what has otherwise been a solid year for GOOGL, which is up 21% year-to-date, and crossed the $1,000 level for the first time in early June. However, today's drop has the stock on pace to close below its recently supportive 40-day moving average for the first time since mid-April.

Analysts have stuck by GOOGL as the EU probe has unfolded. Of the 26 brokerages covering the stock, 23 rate it a "buy," and 20 of those are "strong buys."

Wireless Partnership Has Sprint Stock Surging

Sprint stock is up 5.6% to trade at $8.46, after news broke of a possible wireless partnership with Charter Communications and Comcast. On the charts, Sprint is bouncing from its 200-day moving average, and looking to reclaim its perch in positive year-to-date territory.

Options traders have been strongly bullish on S lately. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Sprint boasts a 10-day call/put volume ratio of 4.85, which ranks in the 95th percentile of its annual range. This means calls have been purchased over puts at a near annual-high clip.

Ugly Migraine Drug Data Hits ALDR Shares

Alder Biopharmaceutical stock has cratered, down nearly 18% to trade at $15.40 after late-stage trial data for its episodic migraine drug left investors unimpressed. Today's bearish gap -- and new two-year low of $13.80 -- only adds to what has been a rough year for the biopharmaceutical stock, which is down 26% year-to-date.

Increased attention from short sellers isn't helping the case for ALDR stock. Short interest grew by more than 9% during the last two reporting periods, and over 22% of the stock's total available float is currently sold short. At ALDR's average daily volume, it would take nearly three weeks to repurchase all of those pessimistic positions. 

Celebrate 40 Years of Schaeffer's With 4 FREE Stock Picks!


 




 
Special Offers from Schaeffer's Trading Partners